DSIP (delta sleep-inducing peptide): what the research says
One of the more puzzling peptides in the literature — studied for nearly 50 years with a mechanism that remains only partially understood.
TL;DR
- DSIP is a nine-amino-acid neuropeptide first isolated from rabbit cerebral venous blood in 1977, initially observed to induce delta-wave sleep in animal models.
- Human sleep-architecture data is limited and inconsistent; the mechanism of action is not fully characterized.
- FDA removed DSIP from Category 2 on April 22, 2026. In July 2026, an FDA advisory committee voted against adding it to the 503A bulks list.
What it is
Delta sleep-inducing peptide (DSIP) is a nonapeptide — nine amino acids — first described by Monnier et al. in 1977 after being extracted from the cerebral venous blood of sleeping rabbits. When injected into awake rabbits, it appeared to induce slow-wave (delta) sleep, which gave it its name. The observation sparked significant research interest in the 1980s and 1990s. DSIP has since been detected in various tissues including the hypothalamus, pituitary, and peripheral organs, suggesting it may have regulatory roles beyond sleep alone — though these remain poorly defined.
How it works
The honest answer is that the mechanism is not well-established. DSIP has been proposed to modulate the HPA axis (hypothalamic-pituitary-adrenal axis), interact with sigma receptors, and influence corticotropin release — but no single, clean mechanism has been confirmed in peer-reviewed literature. Unlike GHRH or ghrelin analogs, there is no well-characterized receptor that DSIP is known to bind with established pharmacological clarity. This mechanistic uncertainty is a significant limitation when evaluating its clinical potential.
Who asks about it
People come to DSIP when they're investigating sleep quality from a research angle, often after having read about it in peptide forums or longevity publications. It appeals because sleep architecture — particularly slow-wave sleep — is genuinely important for GH secretion, cognitive function, and metabolic health. The frustrating reality is that the compound with the promising name has a thinner scientific foundation than its decades of study might suggest.
What the research says
A 1986 review in Peptides by Graf and Kastin examined the accumulated DSIP literature, including sleep effects in animals and early therapeutic work. Some small human studies in the 1980s reported changes in sleep EEG parameters after DSIP administration, but results were inconsistent across labs and subject populations. Methodological differences — route of administration, timing, population selection — made direct comparison difficult. No large, well-controlled randomized trials in humans have been completed. The review concluded that DSIP's physiological functions and mechanism of action "remain to be established."
Regulatory status
Beyond the thin evidence base, DSIP's regulatory status changed in 2026. FDA removed DSIP (emideltide) from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, DSIP is not in any FDA 503A category and is not on the 503A bulks list. At its July 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted against recommending emideltide (DSIP) for the Section 503A bulk drug substances list. The committee is advisory, and FDA makes the final decision. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
The Halftime POV
DSIP is a case study in why the age of a research compound doesn't equal the depth of the evidence. Nearly five decades of publication haven't resolved the basic mechanism. That's not a reason to dismiss it — the sleep architecture question it raises is genuinely important. It is a reason to keep it in the "watch carefully" category while regulatory and scientific clarity develop.
Related reading:
FAQ
Q: What is DSIP? A: DSIP (delta sleep-inducing peptide) is a nonapeptide first isolated in 1977 from rabbit cerebral venous blood during slow-wave sleep. It was isolated based on the hypothesis that a naturally occurring peptide was responsible for promoting delta-wave (deep) sleep. Subsequent research has produced mixed results on this hypothesis.
Q: Does DSIP actually improve sleep? A: The published literature on DSIP is mixed. Some animal studies showed sleep-promoting effects following administration; human studies have been less consistent. A review of available data does not support a straightforward sleep-promoting mechanism comparable to pharmaceutical sleep aids. The compound's effects on human sleep architecture remain incompletely characterized.
Q: What is DSIP's compounding status? A: FDA removed DSIP (emideltide) from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, DSIP is not in any FDA 503A category and is not on the 503A bulks list. At its July 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted against recommending emideltide (DSIP) for the Section 503A bulk drug substances list. The committee is advisory, and FDA makes the final decision. This page is education only and does not cover sourcing.
Disclaimer
DSIP was previously in FDA's Category 2. FDA removed it from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. This article is educational and is not medical advice.
Sources
- Graf MV, Kastin AJ. "Delta-sleep-inducing peptide (DSIP): an update." — Peptides, 1986
- Schneider-Helmert D. "Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior." — Int J Clin Pharmacol Ther Toxicol, 1981
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is DSIP?
DSIP (delta sleep-inducing peptide) is a nonapeptide first isolated in 1977 from rabbit cerebral venous blood during slow-wave sleep. It was isolated based on the hypothesis that a naturally occurring peptide was responsible for promoting delta-wave (deep) sleep. Subsequent research has produced mixed results on this hypothesis.
Does DSIP actually improve sleep?
The published literature on DSIP is mixed. Some animal studies showed sleep-promoting effects following administration; human studies have been less consistent. A review of available data does not support a straightforward sleep-promoting mechanism comparable to pharmaceutical sleep aids. The compound's effects on human sleep architecture remain incompletely characterized.
What is DSIP's compounding status?
FDA removed DSIP (emideltide) from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, DSIP is not in any FDA 503A category and is not on the 503A bulks list. At its July 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted against recommending emideltide (DSIP) for the Section 503A bulk drug substances list. The committee is advisory, and FDA makes the final decision. This page is education only and does not cover sourcing.
